Evaluation of pharmacologic therapies accompanied by behavioural therapy on smoking cessation success: a prospective cohort study in Turkey

References

• World Health Organization. WHO report on the global tobacco epidemic 2013 [Updated 2013; cited 2014 Oct 30]. Available from: http://www.who.int/tobacco/global_report/2013/en/
   Google Scholar
• Gunay T, Pekel O, Simsek H, et al. Smoking habits and cessation success, what differs among adults and elderly? Saudi Med J. 2014;6:585–589.
   Google Scholar
• Global adult tobacco survey, Ankara, Turkey 2012 [cited 2016 Jan 30]. Available from: http://www.who.int/tobacco/surveillance/survey/gats/report_tur_2012.pdf?ua=1
   Google Scholar
• Turkish Statistical Institute. Global adult tobacco survey, Ankara, Turkey 2012 [Updated 2012; cited 2013 Oct]. Available from: http://www.tuik.gov.tr/PreHaberBultenleri.do?id=13425
   Google Scholar
• Ozdemir L, Kocoğlu G, Sümer H, et al. Frequency of some chronic diseases and risk factors among the elderly people in Sivas, Turkey. Çukurova Med J. 2005;27:89–94. Turkish.
   Google Scholar
• Yengil E, Çevik C, Demirkıran G, et al. Smoking among medical school students and attitudes against smoking. Konuralp Med J. 2014;6(3):1–7.
   Google Scholar
• Andreas S, Chenot FJ, Diebold R, et al. Effectiveness of varenicline as an aid to smoking cessation in primary care: An observational study. Eur Addict Res. 2013;1:47–54. doi: 10.1159/000341638
   Web of Science ®Google Scholar
• Scallan C, Doonan RJ, Daskalopoulou SS. The combined effect of hypertension and smoking on arterial stiffness. Clin Exp Hypertens. 2010;6:319–328. doi: 10.3109/10641960903443558
   Web of Science ®Google Scholar
• Sezer H, Akkurt I, Guler N, et al. A case control study on the effect of exposure to different substances on the development of COPD. Ann Epidemiol. 2006;1:59–62. doi: 10.1016/j.annepidem.2004.12.014
   Web of Science ®Google Scholar
• Merdad LA, AlZahrani MS, Farsi JM. Smoking habits among Saudi female university students: prevalence, influencing factors and risk awareness. Ann Saudi Med. 2007;5:366–369. doi: 10.5144/0256-4947.2007.366
   Web of Science ®Google Scholar
• Larzelere MM, Williams DE. Promoting smoking cessation. Am Fam Physician. 2012;6:591–598.
   Google Scholar
• U.S. Preventive Services Task Force. Counseling and intervention stop revent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. preventive services task force: reaffirmation recommendation statement. Ann Intern Med. 2009;8:551–555.
   Google Scholar
• Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2005;2:CD001007.
   Google Scholar
• Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005;2:CD001292.
   Google Scholar
• 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. public health service clinical practice guideline executive summary. Respir Care. 2008;9:1217–1222.
   Google Scholar
• Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose Throat J. 1990;11:763–765.
   Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;1:47–55. doi: 10.1001/jama.296.1.47
   Web of Science ®Google Scholar
• Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;6:664–675.
   Google Scholar
• Zincir SB, Zincir S, Kaymak E, et al. Comparison of the effectiveness of varenicline, extended-release bupropion and nicotine replacement therapy on the success and the maintenance of a smoking cessation program. BCP. 2013;3:224–230. doi: 10.5455/bcp.20130313045037
   Web of Science ®Google Scholar
• Ucar E, Araz O, Yilmaz N, et al. Effectiveness of pharmacologic therapies on smoking cessation success: three years results of a smoking cessation clinic. Multidiscip Respir Med. 2014;1:9. doi: 10.1186/2049-6958-9-9
   Google Scholar
• Tonstad S, Tonnesen P, Hajek P, et al. Varenicline phase 3 study group, effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;1:64–71. doi: 10.1001/jama.296.1.64
   Web of Science ®Google Scholar
• Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015;313(7):687–694. doi: 10.1001/jama.2015.280
   PubMed Web of Science ®Google Scholar
• Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007;6:1040–1056. doi: 10.1016/j.clinthera.2007.06.012
   Web of Science ®Google Scholar
• Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebocontrolled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, a new therapy for smoking cessation in asian smokers. Clin Ther. 2007;6:1027–1039. doi: 10.1016/j.clinthera.2007.06.011
   Web of Science ®Google Scholar
• Boudrez H, Gratziou C, Messig M, et al. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Curr Med Res Opin. 2011;4:769–775. doi: 10.1185/03007995.2011.557718
   Web of Science ®Google Scholar
• Okuyemi K, Nollen N, Ahluwalıa J. Interventions to facilitate smoking cessation. Am Fam Physician. 2006;2:262–271.
   Google Scholar
• Çelik İ, Yüce D, Hayran M, et al. Nationwide smoking cessation treatment support program-Turkey project. Health Policy. 2015;1:50–56. doi: 10.1016/j.healthpol.2014.11.017
   Web of Science ®Google Scholar